Certainly, when you step back and think about the payment authorities that we're seeking from Parliament to address the vaccines—and in the response to Mr. Paul-Hus and his question—it adds up to about $9.2 billion. I gave a breakdown of what that is.
The payment authorities have come in different forms. Because the crisis started in March and supplementary estimates (A) weren't until June, Parliament approved Bill C-13, which included the Public Health Events of National Concern Payments Act.
Many of the supports that we're looking at are partially supported through what we call the “statutory” forecast side of the main and supplementary estimates, but then there's the voted component. What happened was that, at the end of December, the statutory authority under the Public Health Events of National Concern Payments Act expired, so many of the initiatives that were being supported under the payment authority have migrated over to the voted side. That's why you are seeing it effectively listed on the voted.
If you look on the statutory forecast side, you're often seeing an offsetting of reduction amount. On a voted basis, it seems like a very large amount that's coming late, but on a net basis, there are only a couple of measures that are really new.
There's the $485 million for the procurement of test supplies and testing production, which is going to the provinces and territories through the provision of test kits and supplies to supplement the existing testing capacity that they have.
There's $50 million effectively to support the surge in demand for distress centres during and following the COVID-19 pandemic, and $208 million, which is being used to stabilize key resources and operations in the agency.
It can be a challenge to see through that, but that's why, in a way, we put this on the InfoBase, because it's easier to track in that pane.